OpenAI acquires Orchestra Bio, an agent platform for coordinating drug development

OpenAI announced on October 20, 2026 that it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is combining Orchestra's team and technology with Rosalind, its AI models and tools for life sciences research. Deal terms are not stated on the page.